Form 4: IRADIMED CFO Sells Shares, Exercises RSUs

IRADIMED Corporation's CFO, John Glenn, reported sales of common stock and the exercise of restricted stock units on December 11, 2025, under a pre-arranged plan.

Summary

• John Glenn, Chief Financial Officer of IRADIMED CORP (IRMD), reported multiple transactions on December 11, 2025.
• Glenn sold a total of 15,000 shares of common stock, comprising 14,468 shares at a weighted average price of $97.26 and 532 shares at $98.09.
• He acquired 1,812 shares of common stock through the conversion of Restricted Stock Units (RSUs).
• An additional 714 shares were disposed of at $97.38 to cover tax obligations related to the RSU vesting.
• Following these transactions, Glenn directly beneficially owns 8,460 shares of common stock and 3,624 Restricted Stock Units.
• The reported transactions were executed under a Rule 10b5-1(c) plan.

Sentiment

Score: 4

Explanation: While the RSU vesting is a positive for executive compensation, the significant net sale of common stock by a key executive, even under a 10b5-1 plan, generally carries a slightly negative sentiment as it reduces direct insider ownership. The pre-planned nature mitigates the negative impact somewhat.

Positives

• The exercise of Restricted Stock Units (RSUs) indicates a portion of the CFO's long-term incentive compensation has vested, aligning management's interests with shareholders.

Negatives

• The Chief Financial Officer sold a significant net amount of common stock (13,902 shares) in the open market, reducing his direct ownership.

Risks

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived by investors as a lack of confidence in the company's near-term prospects by a key executive.
• The reduction in direct common stock ownership by the Chief Financial Officer could be interpreted as a decrease in management's direct financial alignment with common shareholders.

Future Outlook

NA

Industry Context

This filing reports routine insider transactions for a publicly traded company's Chief Financial Officer. Such transactions are common across industries as part of executive compensation and personal financial planning, especially when executed under a Rule 10b5-1 plan.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive could be perceived as a signal, though mitigated by the 10b5-1 plan. The conversion of RSUs into common stock slightly increases the outstanding share count, leading to minor dilution.
• Employees: The vesting of RSUs is a standard component of executive compensation, which can be a positive for employee morale and retention at the executive level.

Next Steps

• The remaining 3,624 Restricted Stock Units will vest in two additional equal annual installments after December 11, 2025.

Key Dates

Recommendation

The filing details routine insider transactions, including the exercise of restricted stock units and subsequent sales, all executed under a pre-arranged 10b5-1 plan. While the net reduction in the CFO's direct common stock ownership could be viewed cautiously, the pre-planned nature suggests these are not discretionary sales based on new material information. A Form 4 alone typically does not provide sufficient information to warrant a strong buy or sell recommendation, thus a 'hold' stance is appropriate pending further company-specific news or financial disclosures.

Keywords

IRADIMED CORP, IRMD, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, CFO, John Glenn, Equity Incentive Plan, 10b5-1 Plan